Cytek Biosciences Inc (CTKB)vsEdwards Lifesciences Corp (EW)
CTKB
Cytek Biosciences Inc
$4.09
-5.54%
HEALTHCARE · Cap: $559.19M
EW
Edwards Lifesciences Corp
$85.96
-1.70%
HEALTHCARE · Cap: $49.01B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 2987% more annual revenue ($6.30B vs $204.17M). EW leads profitability with a 17.4% profit margin vs -36.2%. EW earns a higher WallStSmart Score of 61/100 (C+).
CTKB
Hold41
out of 100
Grade: D
EW
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+42.8%
Fair Value
$7.62
Current Price
$4.09
$3.53 discount
Margin of Safety
+68.7%
Fair Value
$253.29
Current Price
$85.96
$167.33 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 73.5% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Strong operational efficiency at 31.2%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
16.7% revenue growth
Areas to Watch
Smaller company, higher risk/reward
ROE of -22.6% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : CTKB
The strongest argument for CTKB centers on EPS Growth, Debt/Equity, Price/Book.
Bull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : CTKB
The primary concerns for CTKB are Market Cap, Return on Equity, Free Cash Flow.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.
Key Dynamics to Monitor
CTKB profiles as a turnaround stock while EW is a growth play — different risk/reward profiles.
CTKB carries more volatility with a beta of 1.19 — expect wider price swings.
EW is growing revenue faster at 16.7% — sustainability is the question.
CTKB generates stronger free cash flow (-5M), providing more financial flexibility.
Bottom Line
EW scores higher overall (61/100 vs 41/100), backed by strong 17.4% margins and 16.7% revenue growth. CTKB offers better value entry with a 42.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cytek Biosciences Inc
HEALTHCARE · MEDICAL DEVICES · USA
Cytek Biosciences Inc (CTKB) is at the forefront of multi-parameter flow cytometry, offering advanced cell analysis solutions that drive innovation in the life sciences industry. The company's proprietary technologies play a critical role in pivotal research fields such as immunology, cancer diagnostics, and drug development, addressing the growing demand for high-precision cellular analysis. Cytek’s dedication to innovation, coupled with its robust customer support, positions it as a significant player within the biotechnology sector. With a comprehensive product range and a solid market footprint, Cytek is well-equipped to facilitate groundbreaking discoveries that can dramatically enhance healthcare outcomes.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?